Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prevalence and Clinical Significance of Anti-annexin A2 Antibodies in COVID-19 Infection

NCT05242159 is registered in ClinicalTrials.gov with Centre Hospitalier Universitaire, Amiens as lead sponsor.

NCT NCT05242159
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05242159 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prevalence and Clinical Significance of Anti-annexin A2 Antibodies in COVID-19 Infection
Lead sponsor
Centre Hospitalier Universitaire, Amiens
Phase
Observational
Overall status
Recruiting
Start date
May 28, 2021
Completion date
June 30, 2026
Enrollment
300 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19